首页> 外国专利> TRADITIONAL CHINESE MEDICINE COMPOUND COMBINATION AND ITS APPLICATION IN RESISTANCE AGAINST PROSTATE CANCER

TRADITIONAL CHINESE MEDICINE COMPOUND COMBINATION AND ITS APPLICATION IN RESISTANCE AGAINST PROSTATE CANCER

机译:中药复方及其在抗前列腺癌中的应用。

摘要

A traditional Chinese medicine compound combination with the anti-prostate cancer effect and its application. The traditional Chinese medicine compound combination comprises the following traditional Chinese medicine raw materials by weight: 4 to 12 parts of bark of Ailanthus altissima, 12 to 30 parts of Hedyotis diffusa, 3 to 15 parts of Curcuma zedoaria, 15 to 30 parts of Salvia miltiorrhiza, 5 to 15 parts of Prunella vulgaris, and 4 to 12 parts of Glycyrrhiza uralensis. For the traditional Chinese medicine compound combination with the anti-prostate cancer effect, the materials are selected and combined according to the theory of traditional Chinese medicine and the pathogenesis of prostate cancer, and the proportions of the components are scientific and reasonable. Results of pharmacology experiments and clinical experiments show that the traditional Chinese medicine compound has a good anti-prostate cancer effect, and not only can significantly inhibit the proliferation and growth of prostate cancer, but also can inhibit the migration, invasion, and metastasis of prostate cancer, significantly improves the quality of life of a tumor-burdened mice, and improves immune indexes of the tumor-burdened mice. In addition, administration of the compound is convenient and simple, and the compound brings no obvious adverse reaction. The traditional Chinese medicine compound can be developed as a new-generation anti-prostate cancer drug, and is expected to become an effective prescription for the treatment of prostate cancer.
机译:具有抗前列腺癌作用的中药复方及其应用。中药复方组合按重量计包括以下中药原料:臭椿皮4至12份,白花蛇舌草12至30份,姜黄3至15份,丹参15至30份,夏枯草5到15份和甘草4到12份。对于具有抗前列腺癌作用的中药复方制剂,根据中医理论和前列腺癌的发病机理选择和结合材料,成分比例科学合理。药理实验和临床实验结果表明,中药复方具有良好的抗前列腺癌作用,不仅可以明显抑制前列腺癌的增殖和生长,还可以抑制前列腺的迁移,侵袭和转移。癌症,可显着改善荷瘤小鼠的生活质量,并改善荷瘤小鼠的免疫指标。另外,该化合物的给药方便且简单,并且该化合物没有明显的不良反应。该中成药可作为新一代抗前列腺癌药物开发,有望成为治疗前列腺癌的有效处方。

著录项

  • 公开/公告号WO2017063562A1

    专利类型

  • 公开/公告日2017-04-20

    原文格式PDF

  • 申请/专利权人 EAST CHINA NORMAL UNIVERSITY;

    申请/专利号WO2016CN101970

  • 发明设计人 YI ZHENGFANG;HU MEICHUN;LIU MINGYAO;

    申请日2016-10-13

  • 分类号A61K36/9066;A61P35;

  • 国家 WO

  • 入库时间 2022-08-21 13:31:23

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号